ClinicalTrials.gg
RecruitingNCT04191811TreVarUpdated Oct 7, 2025

Investigating Neural Response Variability as a Single-patient Predictor of Successful CBT in Clinical Psychiatry

An observational study in Psychiatric Disorder, Depression and Anxiety Disorders, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Karolinska Institutet · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Many psychiatric patients are not sufficiently improved by current interventions. Functional magnetic imaging brain imaging (fMRI) has proven to be a promising method for predicting treatment outcomes in psychiatric treatment. Individuals moment-to-moment variability have not yet been evaluated as a predictor of treatment of three common forms of mental illness: depression, insomnia and health anxiety. The goal is to investigate whether objective measurements of brain function contribute to a better prediction of a patient's success in treatment than experiences and self-reports, e.g., treatment credibility and patients expectations about the treatment. The prediction model will be tested on internet-delivered CBT (iCBT) for depression, insomnia and social anxiety. Patients in each diagnostic group are asked for participation before treatment. The total number of participants in this study will amount to 225 participants. The goal is that 35% consists of healthy controls and that the remaining part is equally distributed between the three diagnostic patient groups.

Being able to better predict how well a psychiatric treatment will work for an individual has great value from both an economic and a treatment perspective. The findings from this study may contribute to increased knowledge about neurobiological complications in mental illness. In the longer term, it can lead to improved routines and help in clinical decision-making when patients should be recommended treatment.

Read the detailed description

Background: There is extensive evidence that cognitive behavioral therapy (CBT) is an effective method of treating common psychiatric disorders such as depression, social anxiety and insomnia. However, access to CBT is very limited. Furthermore, evidence suggest that internet-delivered CBT (iCBT) is as effective as traditional CBT. However, many psychiatric patients are not sufficiently improved by current interventions. Functional brain imaging has proven to be a promising method for predicting treatment outcomes in psychiatric treatment. Calculations on brain signal variability based on the blood-oxygen-level-dependent, BOLD signal (BOLD-fMRI) is a relatively new technique, shown to accurately predict chronological age and cognitive performance. Preliminary data from the investigators' lab suggest that pre-treatment BOLD-fMRI variability is predictive of CBT outcome in patients with social anxiety disorder.

Objectives: The objective of the study is to investigate whether objective measurements of brain function, in comparison with subjective experiences and self-reports (e.g., rating on treatment credibility and patients expectations about the treatment), contribute to better prediction of treatment outcome. The prediction model will be tested on iCBT for three common forms of mental disorders (depression, insomnia and social anxiety). Furthermore, participants will be compared with healthy controls to better understand neurobiological factors that may contribute to mental illness. Preliminary data from the investigators' lab suggest that BOLD-fMRI variability differs between social anxiety disorder participants and healthy individuals.

Method: A sample of outpatients scheduled for iCBT treatment for depression, insomnia or social anxiety at the Internet Psychiatry Unit at Karolinska University Hospital in Huddinge, Stockholm, will be invited to participate in the study. In addition to clinical participants, a healthy control group will be recruited via advertisement in social media. The length of the iCBT intervention is 12 weeks, during which participants engage in web-based treatment modules in a sequential manner, guided though a digital messaging system by a licensed psychologist who provides support and feedback on progress and assignments.

Measuring instruments: Brain imaging is performed before the patients initiate psychiatric treatment. The brain will be examined with structural and functional magnetic resonance imaging (MRI) using an EPI sequence to capture the BOLD signal (Philips 3-Tesla, 32 channel head-coil).

During the online self-referral process and during clinical intake interview, data on a number of potential predictor variables are collected:

  • Within the social-demographic domain: age; gender; relationship status (dichotomized as being single or not); level of education rated on a 7-point scale (1 = less than 7-9 years in school; 2 = 7-9 years in school; 3 = incomplete vocational or secondary school; 4 = vocational school; 5 = secondary school; 6 = university, started but not completed studies; 7 = completed university studies); employment status dichotomized as working full-time or not; having children, living situation (alone, with kids, with partner, other), if they do physical activity weekly or not, if they smoke or not.
  • Within the clinical characteristics domain: duration of illness (years since onset), history of psychotropic medication, if currently on psychotropic medication, history of inpatient psychiatric care, history of depression and attempted suicide, presence of a neuropsychiatric diagnosis (e.g. ADHD or autism spectrum disorder), current or previous psychological treatment and current or previous periods of sick leave.
  • Presence (yes/no) of any comorbid illness is assessed using the the MINI-International Neuropsychiatric Interview (MINI), including bipolar disorder, panic disorder, agoraphobia, social anxiety disorder, mild depressive episode, moderate depressive episode, severe depressive episode, recurrent mild depressive episode, recurrent moderate depressive episode, recurrent severe depressive episode, recurrent depression without current symptoms and dysthymia, generalized anxiety disorder, antisocial personality disorder, anorexia nervosa, bulimia, binge eating disorder and ADHD.
  • Having a family history of mental illness is assessed prior to treatment, screening for having a family history of dependence / substance abuse, bipolar disorder, depression, minor depression, neuropsychiatric condition, anxiety, panic disorder, psychosis, social anxiety disorder, social anxiety disorder-like symptoms, suicide attempts or suicide completed.
  • Treatment process factors including perceived treatment credibility measured during the second week in treatment, measured with the Credibility/Expectancy Questionnaire (CEQ) where patients' attitudes to the credibility of the treatment and expectancy regarding treatment effectiveness are rated. Second, treatment adherence is measured at post-treatment, reflecting the degree of use of the ICBT program operationalized as the total number of activated treatment modules.

Measurements only administered at screening/pre-treatment:

  • Patient Health Questionnare 9 (PHQ-9; all participants)
  • Insomnia Severity Index (ISI; all participants)
  • Liebowitz Social Anxiety Scale - (LSAS-SR; all participants)
  • Panic Disorder Severity Scale - (PDSS-SR; all participants)
  • Social Phobia Inventory (SPIN; all patients)
  • The Alcohol Use Disorders Identification Test (AUDIT; all participants)
  • The Drug Use Disorders Identification Test (DUDIT; all participants)
  • The Adult Self Report Scale (ASRS-V1; all patients)

Behavioural measurements before/while undergoing MRI (all participants):

  • Positive and Negative Affect Schedule (PANAS)
  • Affect (valence and arousal). "How much pleasure or discomfort are you feeling right now? (1-9)" and "How calm or upset do you feel right now? (1-9)"
  • Karolinska Sleepiness Scale (KSS)
  • Subjective unit of discomfort (SUD): fear and distress (0-100)
  • Self-rated health (SRH-7)
  • Social Network Index (SNI)
  • Short Grit Scale (SGI)

Predictors of treatment outcome

  1. Behavioral predictor(s) of treatment outcome:

    • Questions about desired and expected treatment improvement. These include a) treatment credibility and b) modified PHQ-9, LSAS-SR and ISI questionnaires where the participants' expectation after completed treatment is self-rated for each item as well as participants' desire of improvement on a 0-100 scale for each item.
    • Ecological momentary assessments (EMA) with repeated sampling of participants' current behaviors and experiences in real time (4 times/day, during approximately 5 days prior to MRI procedure), including sleep problems, sleepiness, social anxiety, depressive symptoms, fear and discomfort. The purpose is to measure different and varied experiences / feelings over time. Variability in experiences will be compared to the participant's variability in brain function to answer the question of whether emotion variability can predict treatment outcomes. The specific EMA questions include the following: PHQ-2, Karolinska Sleepiness Scale (KSS), item 1 from ISI, item 11 and 15 from LSAS-SR and the subjective units of discomfort (fear and distress).
    • Emotion categorical ambiguity task
  2. Brain-signal variability predictor(s), as derived from the following BOLD-fMRI experiments (all participants):

    • Face localizer task
    • Repetition suppression: faces (neutral, sad, angry, fear), scenes, verbal condition (á 60-90 seconds)
    • Faces
    • Scenes
    • Mooney faces
    • Retinotopy, i.e., traveling-wave method
02

Conditions studied

  • Psychiatric Disorder
  • Depression
  • Anxiety Disorders
  • Insomnia

Keywords

  • Internet-delivered Cognitive Behavior Therapy
  • BOLD-fMRI
  • Moment-to-moment variability
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 150 is below the median of 220 across 391 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Reported in previous studies from the clinic:

  • Depression: mean age 37.9 (SD=11.8) yrs, 33% males, time since symptom debut, years 10.4 (SD=9.9), baseline MADRS-S scores 25.13 (SD=6.67); 72% on current psychotropic medication.
  • Insomnia: mean age 46.1 (SD=13.6) yrs, 70% males, baseline ISI scores 20.4 (SD=3.7); baseline MADRS-S score 25.5 (SD=6.8), 72% on current sleep medication 64%, on antidepressant medication 36%.
  • Social anxiety: mean age 32.51 (SD=8.98), 54% males, baseline LSAS-SR score 71.23 (SD=24.57), time since symptom debut, years 15.95 (SD=10.99), on current psychotropic medication 68% (SD=0.47).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meeting criteria for depression, social anxiety or insomnia. Diagnosis and measures of symptom burden and functional level are made through a structured interview, the Mini-International Neuropsychiatric Interview (M.I.N.I.) and self-assessments of symptoms. Healthy controls should not be relevant to psychiatric treatment nor meet criteria for any psychiatric condition according to the M.I.N.I.
  • Being able to read, write and speak Swedish in order to be able to read the treatment texts and be able to make phone calls.
  • Having basic computer skills to be able to complete surveys via the Internet and access the treatment platform.

Exclusion criteria

Exclusion Criteria:

  • Physical or mental illnesses who are either for treatment (for example, bipolar disorder that can be exacerbated by treatment) or for other reasons need other treatments (e.g. severe depression, suicidal behavior, psychotic illnesses or extensive cognitive difficulties).
  • High alcohol consumption or other ongoing drug use.
  • Answering "yes" to any of the following questions will be excluded for participation: 1) "Have you or have you had any electrical / battery operated implants in your body? For example, a pacemaker, medication pump, neurostimulator, hearing implant, or other electrical / battery controlled implant?" 2) "Have you done any surgery on the abdomen, chest, heart or brain, eyes, ears? For example, vessel clips, or objects such as screws, heart valve, shunt or prosthesis?" 3) "Do you have or have you had any metallic object in your body?" 4) "If a woman, are you pregnant or breastfeeding?" 5) "Do you undergo dialysis or have kidney dysfunction?" Participants who answer yes to these follow-up questions will be interviewed more closely to determine if MRI security can be guaranteed and whether the MRI signal will have significant disruptions, for example due to dental scaffolding. 1) "If you have any abdominal, thoracic, heart or brain, eyes, ears? Do you have any inoperable object that has ferromagnetic properties?" The patient will be asked to consult his doctor about this. 2) "If you have a dental rack, what type of dental rack (fixed or removable, metal plates / rails or wire)"?
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Depression Internet-delivered CBT

    12 weeks of guided internet-delivered CBT for depression.

    Behavioral: Internet-delivered cognitive behavioral therapy for major depressive disorder

  • Insomnia Internet-delivered CBT

    12 weeks of guided internet-delivered CBT for insomnia.

    Behavioral: Internet-delivered cognitive behavioral therapy for insomnia

  • Social Anxiety Internet-delivered CBT

    12 weeks of guided internet-delivered CBT for social anxiety.

    Behavioral: Internet-delivered cognitive behavioral therapy for social anxiety disorder

Interventions

  • BehavioralInternet-delivered cognitive behavioral therapy for major depressive disorder

    Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

  • BehavioralInternet-delivered cognitive behavioral therapy for insomnia

    Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

  • BehavioralInternet-delivered cognitive behavioral therapy for social anxiety disorder

    Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Patient Health Questionnaire 9 - Self Assessment (PHQ-9) to Post-treatment

    The questionnaire has nine items. Overall score ranges from 0 to 27. Lower scores indicates a better outcome.

    Time frame: Up to 6 months

  2. Change from Baseline Insomnia Severity Index - Self Assessment (ISI) to Post-treatment

    The questionnaire has seven items. The overall score ranges from 0 to 28. Lower scores indicates a better outcome.

    Time frame: Up to 6 months

  3. Change from Baseline Liebowitz Social Anxiety Scale - Self Assessment (LSAS-SR) to Post-treatment

    The questionnaire has 48 items. The overall score ranges from 0 to 144. Lower scores indicates a better outcome.

    Time frame: Up to 6 months

Secondary outcomes

  1. Consultation Satisfaction Questionnaire (CSQ-8) to Post-treatment

    The questionnaire has 8 items. The overall score ranges from 8 to 32. Higher scores indicate a better outcome.

    Time frame: 3 months

  2. Social Phobia Inventory - Self Assessment (SPIN) 17 items. Overall score 0-68.

    Self Assessment, 17 items. Overall score 0-68. Lower scores indicates a better outcome.

    Time frame: Up to 6 months

  3. World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

    Self Assessment, 12 items. Overall score 0-100%. Lower scores indicate a better outcome.

    Time frame: Up to 6 months

  4. Change from Baseline Generalized Anxiety Disorder Scale (GAD-7) to Post-treatment

    The questionnaire has seven items. The overall score ranges from 0 to 21. Lower scores indicate a better outcome.

    Time frame: Up to 6 months

  5. Montgomery Åsberg Depression Rating Scale - Self Assessment (MADRS-S)

    Self Assessment, 9 items. Overall score 0-54. Lower scores indicate a better outcome.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Internetpsykiatri
    Huddinge, Stockholm County 14152, Sweden
    Recruiting
08

References and documents

Publications

  • Schwiedrzik CM, Melloni L, Schurger A. Mooney face stimuli for visual perception research. PLoS One. 2018 Jul 6;13(7):e0200106. doi: 10.1371/journal.pone.0200106. eCollection 2018. PubMed 29979727 ↗
  • Wandell BA, Dumoulin SO, Brewer AA. Visual field maps in human cortex. Neuron. 2007 Oct 25;56(2):366-83. doi: 10.1016/j.neuron.2007.10.012. PubMed 17964252 ↗
  • Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002 Jul 19;297(5580):400-3. doi: 10.1126/science.1071829. PubMed 12130784 ↗
  • Wang S, Yu R, Tyszka JM, Zhen S, Kovach C, Sun S, Huang Y, Hurlemann R, Ross IB, Chung JM, Mamelak AN, Adolphs R, Rutishauser U. The human amygdala parametrically encodes the intensity of specific facial emotions and their categorical ambiguity. Nat Commun. 2017 Apr 21;8:14821. doi: 10.1038/ncomms14821. PubMed 28429707 ↗
  • Garrett DD, Kovacevic N, McIntosh AR, Grady CL. Blood oxygen level-dependent signal variability is more than just noise. J Neurosci. 2010 Apr 7;30(14):4914-21. doi: 10.1523/JNEUROSCI.5166-09.2010. PubMed 20371811 ↗
  • Garrett DD, Nagel IE, Preuschhof C, Burzynska AZ, Marchner J, Wiegert S, Jungehulsing GJ, Nyberg L, Villringer A, Li SC, Heekeren HR, Backman L, Lindenberger U. Amphetamine modulates brain signal variability and working memory in younger and older adults. Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7593-8. doi: 10.1073/pnas.1504090112. Epub 2015 Jun 1. PubMed 26034283 ↗
  • Mansson KN, Frick A, Boraxbekk CJ, Marquand AF, Williams SC, Carlbring P, Andersson G, Furmark T. Predicting long-term outcome of Internet-delivered cognitive behavior therapy for social anxiety disorder using fMRI and support vector machine learning. Transl Psychiatry. 2015 Mar 17;5(3):e530. doi: 10.1038/tp.2015.22. PubMed 25781229 ↗
  • Hedman E, Ljotsson B, Kaldo V, Hesser H, El Alaoui S, Kraepelien M, Andersson E, Ruck C, Svanborg C, Andersson G, Lindefors N. Effectiveness of Internet-based cognitive behaviour therapy for depression in routine psychiatric care. J Affect Disord. 2014 Feb;155:49-58. doi: 10.1016/j.jad.2013.10.023. Epub 2013 Oct 26. PubMed 24238951 ↗
  • Blom K, Jernelov S, Kraepelien M, Bergdahl MO, Jungmarker K, Ankartjarn L, Lindefors N, Kaldo V. Internet treatment addressing either insomnia or depression, for patients with both diagnoses: a randomized trial. Sleep. 2015 Feb 1;38(2):267-77. doi: 10.5665/sleep.4412. PubMed 25337948 ↗
  • Hedman E, Andersson E, Ljotsson B, Axelsson E, Lekander M. Cost effectiveness of internet-based cognitive behaviour therapy and behavioural stress management for severe health anxiety. BMJ Open. 2016 Apr 25;6(4):e009327. doi: 10.1136/bmjopen-2015-009327. PubMed 27113231 ↗
  • Mansson KNT, Waschke L, Manzouri A, Furmark T, Fischer H, Garrett DD. Moment-to-Moment Brain Signal Variability Reliably Predicts Psychiatric Treatment Outcome. Biol Psychiatry. 2022 Apr 1;91(7):658-666. doi: 10.1016/j.biopsych.2021.09.026. Epub 2021 Oct 12. PubMed 34961621 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jan 2026, 45 months after the start.

Of 150 non-industry observational studies under Mental Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 77. This study's planned 45 months is above that.

Counting every sponsor, half of 157 studies reached it within 37 months; a quarter within 13 and three quarters within 77.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 10, 2019
StartActual
Apr 1, 2022
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04191811
Responsible party
Kristoffer N T Månsson (Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Dec 10, 2019
Start date
Apr 1, 2022
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Oct 7, 2025

Study contacts

Kristoffer Kristoffer, PhD
Contact
kristoffer.mansson@ki.se
+46(0)705803267
Viktor Kaldo, PhD
Contact
viktor.kaldo@ki.se
Kristoffer Kristoffer, PhD
principal investigator · Department of Clinical Neuroscience, Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion